LifeScience Clinical & Diagnostic
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale...
March 27, 2026 | News
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that it has received clearance from the Center for Drug Evaluation (CDE) of China's ...
March 26, 2026 | News
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality med...
March 24, 2026 | News
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
March 24, 2026 | News
Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS &plusm...
March 23, 2026 | News
GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy...
March 23, 2026 | News
Alphamab Oncology announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispec...
March 23, 2026 | News
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
March 19, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...
March 18, 2026 | News
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101...
March 18, 2026 | News
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease...
March 18, 2026 | News
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food ...
March 17, 2026 | News
Most Read
Bio Jobs
News